P541 Diagnosis, management, and evolution of acute pancreatitis secondary to thiopurines in patients with Inflammatory Bowel Disease: an ENEIDA registry study

Abstract Background Treatment with thiopurines in patients Inflammatory Bowel Disease (IBD) may be associated different adverse effects, including acute pancreatitis. Our aims were to evaluate the clinical presentation, severity and management of pancreatitis related IBD. Methods IBD secondary treatment for identified from prospectively maintained ENEIDA registry Spanish Working Group on Crohn's Ulcerative Colitis (GETECCU). We included those who met Atlanta diagnostic criteria had an imaging test that ruled out biliary origin Investigators at each participating centre provided additional information evolution management. Results 290 34 centres; 54% women, 84% Crohn’s disease 56% smokers. Five (1.7%) before, but no patient chronic The median age was 36 years (IQR 27-50). In 94% cases, occurred after first thiopurine drug. Azathioprine used 97% cases (median dose 2.3 mg/kg/day 2-2.5)), 6% treated mercaptopurine (1.5 1-1.5)). Pancreatitis diagnosed a 23 days 14-35) since start thiopurines. 81% required hospitalization 5 4-7). Four (1.4%) severe pancreatitis, 16 (5.5%) moderate, rest mild, according classification. No epidemiological or factors Thiopurine withdrawn all upon diagnosis After 2 months 1-28) received again (5 same, 11 thiopurine), suffering new episode 12 (75%) 5-34). smokers (n=7), compared 9 (56%) non-smokers former (p=0.04, RR 1.8; 95% CI 1.1-3.2). Conclusion Acute is mild most patients, usually appearing during month treatment. reintroduction thiopurines, although feasible some not recommended due high risk developing especially